Cell and Gene Therapy, Industry
September 29, 2022
Via: Biopharma DiveSarepta Therapeutics has asked the Food and Drug Administration to approve its gene therapy for Duchenne muscular dystrophy under accelerated review, the company said Thursday. The biotechnology company’s application for SRP-9001, also known as delandistrogene moxeparvovec, is primarily based on […]
February 27, 2024
March 8, 2024
February 29, 2024